StreetInsider.com News Articles

Form 4 Septerna, Inc. For: Jun 12 Filed by: Shaikhly Samira

Tue, 16 Jun 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260616/26655749.html

Form 4 Septerna, Inc. For: Jun 12 Filed by: Shaikhly Samira

Tue, 16 Jun 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260616/26655749.html

Form 144 Septerna, Inc. Filed by: Shaikhly Samira

Fri, 12 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26641590.html

Form 144 Septerna, Inc. Filed by: Shaikhly Samira

Fri, 12 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26641590.html

Guggenheim Starts Septerna Inc (SEPN) at Buy

Thu, 11 Jun 2026 06:07:25 -0400

Guggenheim analyst Seamus Fernandez initiates coverage on Septerna Inc (NASDAQ: SEPN) with a Buy rating and a price target of $52.00.

For an analyst ratings summary and ratings history on Septerna Inc click here. For more ratings news on Septerna Inc click here.

Shares of Septerna Inc closed at $30.47 yesterday.

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Mon, 08 Jun 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago.

The presentation will highlight the pharmacologic profile of SEP-479, a potent, selective small molecule PTH1R agonist being developed for the treatment of hypoparathyroidism, including robust in vitro and in vivo activity supporting its potential as an oral therapy. SEP-479 is currently

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Mon, 08 Jun 2026 08:00:00 -0400

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Mon, 08 Jun 2026 08:00:00 -0400

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Mon, 08 Jun 2026 08:00:00 -0400

Septerna Inc (SEPN) PT Raised to $53 at Raymond James

Mon, 08 Jun 2026 06:24:38 -0400

Raymond James analyst Martin Auster raised the price target on Septerna Inc (NASDAQ: SEPN) to $53.00 (from $47.00) while maintaining a Strong Buy rating.

The analyst comments "In this note, we preview the ongoing Phase 1 trial for SEP-479 (PTH1R agonist) with data expected in ~late 2026/early 2027. We see SEPN as among the most compelling names in our coverage universe given the depth and quality of pipeline assets with multiple paths for success. While SEPN’s X2 inhibitor (SEP-631) has effectively established attractive PK and target engagement, we believe SEP-479 overwhelmingly remains the focus of investors pending clarity around derisking clinical

Septerna Inc (SEPN) PT Raised to $53 at Raymond James

Mon, 08 Jun 2026 06:24:38 -0400

Raymond James analyst Martin Auster raised the price target on Septerna Inc (NASDAQ: SEPN) to $53.00 (from $47.00) while maintaining a Strong Buy rating.

Form 4 Septerna, Inc. For: Jun 01 Filed by: Shaikhly Samira

Wed, 03 Jun 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260603/26600908.html

Form 4 Septerna, Inc. For: Jun 01 Filed by: Shaikhly Samira

Wed, 03 Jun 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260603/26600908.html

Form 4 Septerna, Inc. For: May 26 Filed by: Shaikhly Samira

Thu, 28 May 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260528/26569220.html

Form 4 Septerna, Inc. For: May 26 Filed by: Shaikhly Samira

Thu, 28 May 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260528/26569220.html

Form 144 Septerna, Inc. Filed by: Shaikhly Samira

Tue, 26 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260526/26550730.html

Form 144 Septerna, Inc. Filed by: Shaikhly Samira

Tue, 26 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260526/26550730.html

H.C. Wainwright Reiterates Buy Rating on Septerna Inc (SEPN)

Wed, 13 May 2026 07:52:44 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $40.00 price target on Septerna Inc (NASDAQ: SEPN).

The analyst commented: "Septerna's oral small molecule MRGPRX2 negative allosteric modulator (NAM) SEP-631 was well-tolerated in a Phase 1 trial, demonstrated a pharmacokinetic profile supportive of once-daily oral dosing and produced robust, dose-dependent suppression of icatibant-induced skin wheal formation. Septerna continues preparations to initiate a Phase 2b trial of SEP-631 in chronic spontaneous urticaria (CSU) in 2H26 following completion of long-term toxicology studies. The company expects to subsequently evaluate SEP-631 in an open-label study in chronic inducible urticaria patients with symptomatic dermatographism. Septerna

Septerna, Inc. (SEPN) Tops Q1 EPS by 55c

Mon, 11 May 2026 17:41:56 -0400

Septerna, Inc. (NASDAQ: SEPN) reported Q1 EPS of ($0.19), $0.55 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $26.52 million.

For earnings history and earnings-related data on Septerna, Inc. (SEPN) click here.

Form 10-Q Septerna, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469098.html

Form 10-Q Septerna, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469098.html

Form 8-K Septerna, Inc. For: May 11

Mon, 11 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260511/26468944.html

Form 8-K Septerna, Inc. For: May 11

Mon, 11 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260511/26468944.html

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:01:00 -0400

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026

Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism

Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:01:00 -0400

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026

Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism

Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029